<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450266</url>
  </required_header>
  <id_info>
    <org_study_id>004</org_study_id>
    <nct_id>NCT02450266</nct_id>
  </id_info>
  <brief_title>Study Comparing MRI/Ultrasound Fusion-guided Prostate Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy</brief_title>
  <acronym>PROFUSE</acronym>
  <official_title>Prospective Multicenter, Randomized Study Comparing the Diagnostic Efficacy of a Targeted MRI/Ultrasound Fusion-guided Prostate Biopsy Versus a Systematic Transrectal Ultrasound-guided Biopsy in Men With at Least on Negative Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be submitted to a multiparametric MRI examination of the prostate.
      Subsequently, all participants will be randomized (1:1) into both study arms. In study arm A
      patients will be submitted to the gold-standard which comprises systematic transrectal
      ultrasound-guided prostate biopsy. In study arm B patients will be submitted to targeted
      prostate biopsy based on the multiparametric MRI findings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In men with previously negative prostate biopsy and persistent elevated prostate-specific
      antigen (PSA) value, it is unclear which biopsy strategy offers the highest detection rate
      for significant prostate cancer. The hypothesis of this study is that targeted MRI/ultrasound
      fusion-guided biopsy improves the detection rates of significant prostate cancers compared
      with systematic transrectal ultrasound-guided prostate biopsy.

      Men with at least one previously negative transrectal ultrasound-guided biopsy and
      persistently elevated PSA values (&gt; 3 ng/ml) or PSA velocity &gt;0.75 ng/ml/p.a. will be
      submitted to a multiparametric MRI examination of the prostate. Subsequently, all
      participants will be randomized (1:1) into both study arms. In study arm A patients will be
      submitted to the gold-standard which comprises systematic transrectal ultrasound--guided
      prostate biopsy. In study arm B patients will be submitted to targeted prostate biopsy based
      on the multiparametric MRI findings. Targeted biopsies will be performed using MRI/ultrasound
      fusion-guided.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of significant prostate cancers</measure>
    <time_frame>One week after biopsy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall detection rate of prostate cancers</measure>
    <time_frame>One week after biopsy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">586</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A: Transrectal ultrasound-guided biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients of arm A receive a systematic transrectal ultrasound-guided prostate biopsy (12-18 biopsy cores depending on individual prostate volume)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: MRI/ultrasound fusion-guided biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of arm B receive a targeted MRI/ultrasound fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Systematic transrectal ultrasound-guided prostate biopsy</intervention_name>
    <description>12-18 systematic biopsy cores</description>
    <arm_group_label>A: Transrectal ultrasound-guided biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI/ultrasound fusion-guided prostate biopsy</intervention_name>
    <description>2 targeted biopsy cores from each prostate lesion</description>
    <arm_group_label>B: MRI/ultrasound fusion-guided biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one negative transrectal ultrasound-guided prostate biopsy

          -  PSA &gt; 3.0 ng/ml or PSA velocity &gt;0.75 ng/ml/p.a.

        Exclusion Criteria:

          -  Known prostate cancer

          -  PSA &gt;50 ng/ml

          -  Previous MRI-targeted prostate biopsy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Arsov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, University Hospital Düsseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Arsov, MD</last_name>
    <phone>+49 211 8108607</phone>
    <email>christian.arsov@med.uni-duesseldorf.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Urology, Charité-Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Miller, MD</last_name>
      <phone>+49 30 8445 2575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Arsov, MD</last_name>
      <phone>+49 211 8108607</phone>
      <email>christian.arsov@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc O Grimm, MD</last_name>
      <phone>+49 3641-935206</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary disease</keyword>
  <keyword>multiparametric MRI</keyword>
  <keyword>targeted prostate biopsy</keyword>
  <keyword>MRI/ultrasound fusion-guided prostate biopsy</keyword>
  <keyword>systematic transrectal ultrasound-guided prostate biopsy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

